Summary
The cataleptic effect of remoxipride was examined in the horizontal bar test after i.v.,i.p. and s.c. administration to male rats. Remoxipride induced immediate catalepsy after high i.v. doses (ED50=49 μmol/kg) while peak effects were seen 60–90 min after i.p. administration (ED50=38 μmol/kg). Following s.c. administration remoxipride failed to produce a statistically significant catalepsy in the 20–100 μmol/kg dose range (ED50 > 100 μmol/kg). In contrast, haloperidol was found to be more effective in inducing catalepsy after i.v. (ED50=0.4 μmol/kg) than after i.p. or s.c. administration (ED50=0.9 μmol/ kg). The atypical antipsychotic profile of remoxipride was more pronounced when the compound was given i.v. or s.c. as compared with the i.p. route. Plasma and brain (striatum and nucleus accumbens) concentrations of remoxipride and its active phenolic metabolites FLA 797(−) and FLA 908(−) were measured by high performance liquid chromatography. The 40 μmol/kg dose of remoxipride resulted in plasma and brain concentrations of remoxipride which were 300–1000-fold higher (depending on the route of administration) than the most potent of the phenolic metabolites, e.g., FLA 797(−). The plasma and brain concentrations of remoxipride and its phenolic metabolites were related to DA D2 receptor blocking potency and to the temporal course and effectiveness to induce catalepsy. This analysis suggested that the unbound concentrations of the phenolic metabolites were too low to play a major role in the DA blocking action of remoxipride. However, FLA 797(−) may contribute marginally to the cataleptic effects following high (i.p.) doses of remoxipride.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Creese I, Sibley DR, Hamblin MW, Leff SE (1983) The classification of dopamine receptors: relationship to radioligand binding. Ann Rev Neurosci 6: 45–71
Fog R, Randrup A, Pakkenberg H (1970) Lesions in corpus striatum and cortex of rat brains and the effect on pharmacologically induced stereotyped, aggressive and cataleptic behaviour. Psychopharmacologia (Berl) 18: 346–356
Hall H, Sällemark M, Jerning E (1986) Effects of remoxipride and some related new substituted salicylamides on rat brain receptors. Acta Pharmacol Toxicol 58: 61–70
Högberg T, Rämsby S, de Paulis T, Stensland B, Csöregh I, Wägner A (1986) Solid state conformations and antidopaminergic effects of remoxipride hydrochloride and a closely related salicylamide, FLA 797, in relation to dopamine receptor models. Mol Pharmacol 30: 345–351
Högberg T, Norinder U, Rämsby S, Stensland B (1987) Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine-D2 antagonist. J Pharm Pharmacol 39: 787–796
Hornykiewicz O, Klawans Jr HL (1978) Mechanism of extrapyramidal side effects of psychotropic agents. In: Clark WG, del Giudice J (eds) Principles of psychopharmacology. Academic Press, New York, pp 297–310
Koffer KB, Berney S, Hornykiewicz O (1978) The role of the corpus striatum in neuroleptic- and narcotic-induced catalepsy. Eur J Pharmacol 47: 81–86
Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K (1990) Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatr Scand 82 [Suppl 358]: 27–36
Lewander T, Westerbergh S-E, Morrison D (1990) Clinical profile of remoxipride — a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr Scand [Suppl 358]: 92–98
Lindström L, Besev G, Stening G, Widerlöv E (1986) An open study of remoxipride, a benzamide derivate in schizophrenia. Psychopharmacology 86: 242–243
Malmberg Å, Jackson DM, Eriksson A, Mohell N (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B and D3 receptors. Mol Pharmacol 43: 749–754
Mohell N, Sällemark M, Rosqvist S, Malmberg Å, Högberg T, Jackson DM (1993) Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. Eur J Pharmacol 238: 121–125
Nilsson LB (1990) Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography. J Chromatogr 526: 139–150
Ögren SO, Hall H, Köhler C, Magnusson O, Lindbom O, Ängeby K, Florvall L (1984) Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102: 459–474
Ögren SO, Florvall L, Hall H, Magnusson O, Ängeby-Möller K (1990) Neuropharmalocigal and behavioural properties of remoxipride in the rat. Acta Psychiatr Scand 82 [Suppl 358]: 21–26
Ögren SO, Thyréen G, Lindeberg A, Amkéus E (1993a) Remoxipride differs from other dopamine receptor antagonists in two tests of catalepsy in the rat. Differential effects on dopamine receptor function in the striatum. Psychopharmacology (submitted)
Ögren SO, Hall H, Widman M, Ängeby-Möller K (1993b) Effects of remoxipride's metabolites on dopamine D2 receptors and receptor functions in the rat. Pharmacol Toxicol (in press)
Ögren SO, Lundström J, Nilsson LB, Widman M (1993c) Dopamine D2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the rat. J Neural Transm [Gen Sect] 93: 187–203
Ögren SO, Rosén L, Fuxe K (1993d) The dopamine D2 antagonists remoxipride acts in vivo on a subpopulation of functionally coupled DA D2 receptors (submitted)
Patris M, Aqussol P, Alby JM, Brion S, Buinat G, Castelnau D, Deluermoz H, Dufour M, Ferreri M, Goudelmand M, Legnay D, Lampiere T, Martin A, Morin D, Tignol J, Vincent T, Albaret C (1990) A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Acta Psychiatr Scand 82: 78–83
Sanberg PR (1980) Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 284: 472–473
Shanker IS (1964) Physiological transport of drugs. Adv Drug Res 1: 71–106
Stanley ME, Glick SD (1976) Interaction of drug effects with testing procedures in the measurement of catalepsy. Neuropharmacology 15: 393–394
Ståhle L, Nilsson LB, Ögren SO (1992) High concentrations of remoxipride in lateral ventricles of the rat after systemic administration. Pharmacol Toxicol 70: 226–227
Tsuneizumi T, Babb SM, Cohen BM (1992) Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol Psychiatry 32: 817–824
Widman M, Nilsson LB, Bryske B, Lundström J (1993) Disposition of remoxipride in different species. Species differences in metabolism. Arzneimittelforschung 43 (I) 3: 287–297
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ögren, S.O., Lundström, J. & Nilsson, L.B. Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profile. J. Neural Transmission 94, 199–216 (1993). https://doi.org/10.1007/BF01277025
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01277025